WARRINGTON, Pa., Nov. 4, 2008 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), reports that, as of the close of business on November 3, the U.S. Food and Drug Administration (FDA) had not yet notified Discovery Labs regarding the target action date and review classification of its Complete Response to the May 2008 Approvable Letter for Surfaxin(r) (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. Taking FDA guidelines into consideration, Discovery Labs had anticipated receipt of notification by October 31, 2008. Discovery Labs will provide another update only after it receives notification from the FDA.
